• Journal of Yeungnam Medical Science
• /
• 제41권2호
• /
• pp.134-138
• /
• 2024

Lung retransplantation (LRT) involves a second or subsequent lung transplant (LT) in a patient whose first transplanted graft has failed. LRT is the only treatment option for irreversible lung allograft failure caused by acute graft failure, chronic lung allograft dysfunction, or postoperative complications of bronchial anastomosis. Prehabilitation (rehabilitation before LT), while patients are on the waiting list, is recognized as an essential component of the therapeutic regimen and should be offered throughout the waiting period from the moment of listing until transplantation. LRT is particularly fraught with challenges, and prehabilitation to reduce frailty is one of the few opportunities to address modifiable risk factors (such as functional and motor impairments) in a patient population in which there is clearly room to improve outcomes. Although rehabilitative outcomes and quality of life in patients receiving or awaiting LT have gained increased interest, there is a paucity of data on rehabilitation in patients undergoing LRT. Frailty is one of the few modifiable risk factors of retransplantation that is potentially preventable. As such, it is imperative that professionals involved in the field of retransplantation conduct research specifically exploring rehabilitative techniques and outcomes of value for patients receiving LRT, because this area remains unexplored.

• Journal of Chest Surgery
• /
• 제57권3호
• /
• pp.319-322
• /
• 2024

Venovenous extracorporeal membrane oxygenation (VV ECMO) is often used in cases of severe respiratory failure, especially in patients considered for lung transplantation. However, because many lung diseases can ultimately result in right heart failure, the treatment of secondary right heart failure can present a challenge when the patient is already under VV ECMO support. In such cases, an oxygenated-right ventricular assist device (OxyRVAD) can be used. OxyRVAD is designed to maintain anterograde blood flow and prevent right ventricular distension. Moreover, the pulmonary arterial cannula can be inserted percutaneously. We report a case in which percutaneous OxyRVAD was successfully implemented to manage right heart failure in a patient with respiratory failure who was on VV ECMO.

• 한국임상약학회지
• /
• 제30권3호
• /
• pp.149-160
• /
• 2020

Background: Basiliximab is used as an alternative to tacrolimus in patients with decreased renal function. However, studies on basiliximab as a maintenance immunosuppressant, particularly in patients with lung transplantation, are limited. Therefore, here, we investigated the efficacy and safety of basiliximab in patients with lung transplantation. Methods: Adult patients with acute kidney injury (AKI) who received lung transplantation at a single general hospital between July 1, 2014 and June 30, 2018, were selected and classified in tacrolimus and basiliximab groups. Both groups received a triple-drug regimen (tacrolimus, mycophenolate mofetil, and steroids). However, tacrolimus was discontinued in the basiliximab group when AKI occurred, and two or more repeat basiliximab doses were administered within 3 months after transplantation. The electronic medical records were analyzed retrospectively. Results: Of the 85 patients who met the selection criteria, 61 and 24 were assigned to the tacrolimus and basiliximab groups, respectively. Significant improvement in renal function was observed in the basiliximab group (p <0.001). However, there were no differences in acute and chronic rejection rates in both the groups. No difference was observed in the incidence rate of complications between the groups, except for chronic kidney disease, which showed higher incidence in the basiliximab group (25.0% vs. 4.9%; p =0.013). Conclusions: We suggest the use of basiliximab as an immunosuppressant alternative to tacrolimus in patients with acute renal failure after lung transplantation. Basiliximab demonstrated effectiveness as an immunosuppressant and improved renal function. Therefore, basiliximab can be used in patients with decreased renal function.

• Tuberculosis and Respiratory Diseases
• /
• 제62권3호
• /
• pp.217-222
• /
• 2007

저자들은 악성흉수 환자에서 가장 많은 치료법으로 선택되고 있는 talc 늑막유착술 이후에 급성 저산소증으로 사망한 환자 2예를 경험하였다. Talc 늑막유착술은 안전하고 효과적인 치료이지만, talc를 5 g 이상 사용하거나, 전신상태가 불량하거나, 반복적인 늑막유착술을 시행한 경우나, 양측에 흉수가 있거나, 늑막유착술 전 2주 이내에 항암요법이나 방사선치료를 한 경우나 폐실질에 전이성병변이 있을 때 예후가 불량하므로 talc 늑막유착술 환자를 선정할 때 주의하여야 하겠다.

• Journal of Chest Surgery
• /
• 제37권12호
• /
• pp.1015-1018
• /
• 2004

폐림프관 평활근종증은 주로 가임기 여성에서 발병하며 점진적으로 호흡부전에 이르게 하는 드문 질환이다. 폐의 혈관, 림프관 그리고 기관지를 구성하는 평활근 세포의 비정상적 과오종성 증식으로 인해 기관지 폐쇄, 낭성 기포로의 변환, 림프관 폐쇄 등의 특징이 있으며 대부분 호흡곤란, 기흉, 기침, 흉통, 객혈, 유미흉 등을 동반한다. 호흡부전을 동반한 말기 페림프관 평활근종증은 페이식이 유일한 치료법으로 국내에서 시도된 적은 있으나 아직 성공사례에 대한 보고가 없었다. 본원에서는 폐림프관 평활근종증을 앓고 있던 말기 호흡부전의 40세 여자 환자에게 좌측 단일 페이식술을 시행하여 좋은 결과를 얻었기에 이를 보고하는 바이다.

• Journal of Chest Surgery
• /
• 제39권4호
• /
• pp.304-309
• /
• 2006

배경: 간질성 폐렴(IP)은 폐암의 발생과 깊은 관련이 있으나 수술 후 경과에 미치는 영향은 아직 밝혀진 바 없다. 본 연구의 목적은 술전 간질성 폐렴과 수술 후 급성 호흡부전의 발생과의 관련성을 알아보기 위한 것이다. 대상 및 방법: 1997년 1월부터 2005년 3월까지 가톨릭대학교 의과대학 부속병원에서 근치적 수술을 시행받은 원발성 폐암환자 672예를 대상으로 후향적인 검토를 시행하였다. 수술 전 흉부 HRCT소견이나 수술 표본의 병리조직 판독서에서 간질성 폐렴이 확인된 환자들을 간질성 폐렴(IP)군으로 구분하여, 비합병(non-IP)군과의 사이에 수술 전 검사치와 암 관련 사항들을 비교 분석하였다. 또한 IP군에서는 급성 호흡부전의 발생군과 비발생군 사이에서 급성 호흡부전의 발생에 영향을 줄 수 있는 상이점들을 분석하였다. 결과: 근치적 수술을 시행 받은 672예 중 28예(4.2%)에서 수술 후 급성 호흡부전증이 합병되었으며, 672예 중 수술 전에 IP의 동반이 확인되었던 증례는 53예(7.9%)였다. IP 동반례에서는 6예(11.3%)에서 수술 후 급성 호흡부전증이 합병되었으며, IP가 없었던 619예에서는 22예(3.6%)에서 합병되었다. 급성 호흡부전증의 합병환자 28예 중 21예에서 사망하여 사망률은 75%였다. 결론: 간질성 폐렴은 폐암 수술 후 급성 호흡부전의 발생과 관련이 있다고 생각되었다.

• Journal of Trauma and Injury
• /
• 제24권2호
• /
• pp.155-158
• /
• 2011

Mechanical ventilation is usually the treatment of choice for severe respiratory failure associated with trauma. However, in case of severe hypoxia, mechanical ventilation may not be sufficient for gas exchange in lungs. Patients with Acute Respiratory Distress Syndrome (ARDS) undergo difficulties in oxygen and carbon dioxide exchange. Extracorporeal Membrane Oxygenation (ECMO) is the ideal therapeutic option for those patients with severe traumatic injuries. ECMO allows lungs to reserve their functions and decreases further lung injuries while increasing survival rate at the same time. We report two cases of patients with traumatic ARDS and Multiple Organ Failure including compromised heart function. The preservation of lung function was successful using ECMO therapy.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권1호
• /
• pp.205-213
• /
• 2014

The outcomes of first-generation EGFR-TKIs (Gefitnib and Erlotinib) have shown great advantages over traditional treatment strategies in patients with non-small cell lung cancer (NSCLC), but unfortunately we have to face the situation that most patients still fail to respond in the long term despite initially good control. Up to now, the mechanism of acquired resistance to EGFR-TKIs has not been fully clarified. Herein, we sought to compile the available clinical reports in the hope to better understanding the subsequent treatment choices, particularly on whether restoring after a drug holiday or switching to another EGFR-TKI is the better option after failure of one kind of EGFR-TKI.

• Journal of Chest Surgery
• /
• 제27권1호
• /
• pp.60-62
• /
• 1994

Pulmonary edema and respiratory failure is uncommon but fatal complications associated with major operations of the lung, especially after pneumonectomy. The extracorporeal membrane oxygenation[ECMO] is quite often used in infants with severe respiratory failure and congenital heart disease which is well documented in the literature. In adults, the results of ECMO is comparatively poor to those found in neonates. We have experienced a case of ECMO applied on a 48 year old male who had respiratory failure after pneumonectomy, and the patient was successfully weaned from bypass. Unfortunately however, the patient expired on postoperative 15 day due to multiorgan failure.

• Tuberculosis and Respiratory Diseases
• /
• 제45권4호
• /
• pp.888-895
• /
• 1998

Malaria is one of the most common infectious diseases in the world. Plasmodium falciparum, accounting for nearly all malaria mortality, kills an estimated 1 to 2 million persons yearly and has several features that make it deadlist of malarias. While cerebral malaria is the most common presentation of severe disease, acute lung injury associated with malaria is uncommon but serious and fatal complication. We report two cases of severe malaria with ARDS and multi-organ failure. All two patients traveled to foreign countries, Kenya, Papua New Guinea where choroquine-resistant malaria is distributed. The first case, which developed cerebral malaria, hypoglycemia, multi-organ failure, and ARDS, treated with quinine and mechanical ventilator, but expired due to oxygenation failure. Autopsy showed acute necrotizing infiltration, diffuse eosinophilic fibrinoid deposits along the alveolar space, and alveolar macrophage with malaria pigment The second case also developed multi-organ failure, followed by ARDS, and was treated with quinine, exchange transfusion, plasmapheresis, and mechanical ventilator. He recovered with residual restrictive lung change after treatment.